| Name | Complement Inhibitor Therapy in Neurodegeneration |
| Summary | Complement system inhibitors (C1q, C3, C5) for neurodegeneration: C1q inhibition (B4, NT-1), C3 inhibitors (pegcetacoplan), C5 inhibitors (eculizumab, ravulizumab). Evidence in AD, PD, ALS, FTD. Mechanism: complement-driven synaptic elimination, microglial opsonization. |
| Linked Hypotheses | 24 hypotheses |